Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
|Videos|November 23, 2016
IMiD Sequencing in Relapsed Myeloma with Keith Stewart, MB, ChB Case 2
IMiD Sequencing in Relapsed Myeloma with Keith Stewart, MB, ChB
Advertisement
Case Scenario 2:
December 2013
- The patient is a 77-year old African American male who was diagnosed 24 months ago with stage III multiple myeloma and not eligible for transplant based on his level of frailty. His cytogenetics were classified as intermediate risk.
- He received treatment with lenalidomide (15 mg daily) and low-dose dexamethasone.
December 2015
- IgA monoclonal protein spike seen on SPEP. M-protein level has risen to 0.6 g/dl.
- He continued to do well functionally.
- Lenalidomide was increased to 25 mg daily.
May 2016
- The patient now complains of increasing back pain, fatigue and weakness. He was hospitalized two months ago for pneumonia.
- Abnormal laboratory findings show:
- Serum beta-2-microglobulin level, 6.2 mg/L
- Albumin level of 2.1 g/dL.
- Creatinine clearance of 32 ml/min
- Skeletal survey shows lytic lesions in the L4/L5 vertebrae.
- Bone marrow biopsy shows 30% involvement by abnormal appearing plasma cells, confirmed by CD138+ IHC stain.
- ECOG performance status is 2.
- The patient was started on pomalidomide, weekly cyclophosphamide, and low-dose dexamethasone.
Advertisement
Related to this article
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5